Alpelisib-Induced Diabetic Ketoacidosis: A Case Report and Review of Literature

CONCLUSION: Although PI3KCA inhibitors remain a promising drug in patients with metastatic breast cancer who have not responded to previous treatment, patients must be closely monitored for adverse effects such as hyperglycemia. Hyperglycemia could be a potentially limiting side effect of alpelisib. The optimal management of hyperglycemia induced by alpelisib warrants further research.PMID:34095470 | PMC:PMC8053625 | DOI:10.1016/j.aace.2020.11.028
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Source Type: research